KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Common Equity (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Common Equity data on record, last reported at -$33.7 million in Q4 2025.

  • For Q4 2025, Common Equity rose 44.04% year-over-year to -$33.7 million; the TTM value through Dec 2025 reached -$33.7 million, up 44.04%, while the annual FY2025 figure was -$33.7 million, 44.04% up from the prior year.
  • Common Equity reached -$33.7 million in Q4 2025 per AQST's latest filing, down from -$4.1 million in the prior quarter.
  • Across five years, Common Equity topped out at -$4.1 million in Q3 2025 and bottomed at -$118.6 million in Q4 2022.
  • Average Common Equity over 5 years is -$71.9 million, with a median of -$66.8 million recorded in 2025.
  • Peak YoY movement for Common Equity: crashed 151.4% in 2021, then soared 90.95% in 2025.
  • A 5-year view of Common Equity shows it stood at -$82.1 million in 2021, then tumbled by 44.34% to -$118.6 million in 2022, then rose by 10.18% to -$106.5 million in 2023, then soared by 43.51% to -$60.2 million in 2024, then surged by 44.04% to -$33.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$33.7 million in Q4 2025, -$4.1 million in Q3 2025, and -$72.6 million in Q2 2025.